Our Science
programs
Acurex’s most advanced program is CU-00048, a next-generation T-type calcium channel modulator for Essential Tremor. The company is building a focused T-type franchise, beginning with CU-00048 and followed by a selective CaV3.2 program. Acurex also maintains a 15-LO neurodegeneration program focused on upstream biology involved in neuroinflammation, ferroptosis, oxidative lipid damage, and neuronal vulnerability.
Our lead clinical opportunity is Essential Tremor, where T-type calcium channel modulation has recenly been clinically validated. Additional areas of interest include movement disorders, pain, ALS, Parkinson’s disease, LRRK2-associated Parkinson’s disease, Friedreich’s ataxia, and broader neuroinflammatory and neurodegenerative conditions.
PARTNER WITH ACUREX
VALIDATED PHARMACOLOGY
Acurex focuses on mechanisms that are biologically validated, druggable, measurable, and clinically translatable. In Essential Tremor, Praxis Precision Medicines has meaningfully advanced the field by validating T-type calcium channel modulation in late-stage clinical development. Acurex is building on this validation with CU-00048, a differentiated T-type modulator designed to combine sustained CNS target engagement, state-dependent pharmacology, and a potential tolerability advantage.
For neurodegeneration, Acurex’s 15-LO program targets upstream biology implicated in neuroinflammation, ferroptosis, oxidative stress, and neuronal injury. Recent clinical trial results with direct LRRK2 inhibition have prompted many in the Parkinson’s field to explore upstream approaches that may better address neuronal vulnerability and disease biology beyond kinase inhibition alone.
